Celladon
Signal active
Organization
Contact Information
Overview
Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.
About
Industries
Biotechnology, Health Care, Hospital, Therapeutics
Founded
2000
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Celladon headquartered in United States, North America, operates in the Biotechnology, Health Care, Hospital, Therapeutics sector. The company focuses on Biotechnology and has secured $29.3B in funding across 192 round(s). With a team of 11-50 employees, Celladon is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Celladon, raised $21.8M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
12
Investors
3
Lead Investors
0
Total Funding Amount
$152.5M
Details
3
Celladon has raised a total of $152.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2004 | Early Stage Venture | |||
| 2005 | Early Stage Venture | 30.0M | ||
| 2009 | Late Stage Venture | 21.8M |
Investors
Celladon is funded by 25 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Venrock | - | FUNDING ROUND - Venrock | 43.0M |
| H&Q Healthcare Investors | - | FUNDING ROUND - H&Q Healthcare Investors | 43.0M |
| Celladon | - | FUNDING ROUND - Celladon | 43.0M |
| Enterprise Partners | - | FUNDING ROUND - Enterprise Partners | 43.0M |
Recent Activity
There is no recent news or activity for this profile.